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ABSTRACT 33	
 Biocompatible, biodegradable polymers are commonly used as excipients to 34	
improve the drug delivery properties of aerosol formulations, in which acetalated dextran 35	
(Ac-Dex) exhibits promising potential as a polymer in various therapeutic applications. 36	
Despite this promise, there is no comprehensive study on the use of Ac-Dex as an 37	
excipient for dry powder aerosol formulations. In this study, we developed and 38	
characterized pulmonary drug delivery aerosol microparticle systems based on spray-39	
dried Ac-Dex with capabilities of (1) delivering therapeutics to the deep lung, (2) 40	
targeting the particles to a desired location within the lungs, and (3) releasing the 41	
therapeutics in a controlled fashion. Two types of Ac-Dex, with either rapid or slow 42	
degradation rates, were synthesized. Nanocomposite microparticle (nCmP) and 43	
microparticle (MP) systems were successfully formulated using both kinds of Ac-Dex as 44	
excipients and curcumin as a model drug. The resulting MP were collapsed spheres 45	
approximately 1 µm in diameter, while the nCmP were similar in size with wrinkled 46	
surfaces, and these systems dissociated into 200 nm nanoparticles upon reconstitution in 47	
water. The drug release rates of the Ac-Dex particles were tuned by modifying the 48	
particle size and ratio of fast to slow degrading Ac-Dex. The pH of the environment was 49	
also a significant factor that influenced the drug release rate. All nCmP and MP systems 50	
exhibited desirable aerodynamic diameters that are suitable for deep lung delivery (e.g. 51	
below 5 µm). Overall, the engineered Ac-Dex aerosol particle systems have the potential 52	
to provide targeted and effective delivery of therapeutics into the deep lung. 53	
 54	
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1. INTRODUCTION 58	
 Pulmonary drug delivery has exhibited promising potential in the treatment of 59	
lung diseases, as it allows for the delivery of a wide range of therapeutics directly and 60	
efficiently to the lungs, thereby increasing local drug concentration, reducing systemic 61	
side effects, providing a rapid onset of pharmaceutical action, and avoiding the first-pass 62	
metabolism associated with the liver (Belotti et al., 2015; Cui et al., 2011; Mansour et al., 63	
2009; Meenach et al., 2012).  The deep lung (alveolar) region can be utilized as a route 64	
for systematic drug delivery due to the enormous surface area available and nearby 65	
plentiful capillary vessels that facilitate drug absorption, the very thin (approximately 0.1 66	
µm) liquid layer over the alveoli that ensures rapid and unhindered drug absorption, and 67	
low enzymatic activity, which enhances drug availability (Collier et al., 2016; Cui et al., 68	
2011; Hoang et al., 2014). As a result, various therapeutics such as antibiotics, proteins, 69	
peptides, anti-cancer drugs (Wu et al., 2014), plasmid DNA (Takashima et al., 2007), 70	
siRNA (Jensen et al., 2010), and anti-tuberculosis (TB) drugs have been employed in 71	
inhalation formulations for the treatment of pulmonary diseases such as asthma, chronic 72	
obstructive pulmonary disease (COPD), cystic fibrosis (CF)-related pulmonary 73	
infections, and lung cancer (Meenach et al., 2013a; Wu et al., 2014). 74	
 Dry powders are a dosage formulation that delivers therapeutics to the lung, in the 75	
form of particles, using a dry powder inhaler (Wu et al., 2014). Compared with liquid 76	
aerosols, these formulations offer additional benefits such as enhanced stability of the 77	
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formulation, controllable particle size for targeting different regions of the lung, and 78	
increased drug loading of hydrophobic payloads (Cohen et al., 2010; Meenach et al., 79	
2013a). Spray drying has proven to be a suitable technology in the preparation of dry 80	
powder therapeutics (Meenach et al., 2013a), as it is capable of producing respirable 81	
microparticles for deep lung delivery with acceptable aerosol dispersion properties 82	
(Belotti et al., 2015). Properties of dry powder particles such as particle size, particle 83	
shape, and surface morphology can be modified by controlling the spray drying 84	
production process, thus providing desirable particle characteristics (Belotti et al., 2015; 85	
Wu et al., 2014).  86	
 Biocompatible, biodegradable polymers such as poly(ε-caprolactone) (PCL) and 87	
poly(lactic-co-glycolic acid) (PLGA) have been used as dry powder formulation 88	
excipients to carry drug molecules, protect drugs from degradation, and impart sustained 89	
release to aerosol formulations (Mansour et al., 2009). However, PLGA and PCL 90	
delivery systems show significant burst release of their payloads due to bulk erosion of 91	
the polymers and it is difficult to control the polymer degradation rate and modulate their 92	
release profiles (Ulery et al., 2011). Acetalated dextran (Ac-Dex) is an acid-sensitive, 93	
biodegradable, biocompatible polymer prepared via a one-step reaction by reversibly 94	
modifying dextran with acetal groups. This modification reverses the solubility properties 95	
of dextran from hydrophilic to hydrophobic, making it possible to form polymeric 96	
particles using standard emulsion or nanoprecipitation techniques. In contrast to other 97	
commonly used polymers such as PLGA, polylactic acid, and PCL, Ac-Dex exhibits 98	
attractive properties suitable for the controlled release of therapeutic payloads. By 99	
controlling the reaction time during the formation of Ac-Dex, the ratio of cyclic acetal 100	
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groups (with a slower degradation rate) to acyclic acetal groups (with a faster degradation 101	
rate) can be adjusted. As a result, the degradation rate of the resulting Ac-Dex can be 102	
tuned from hours to months to suit various applications. Moreover, the acid-sensitivity of 103	
Ac-Dex enables it to degrade faster in lower pH environments, such as lysosomes in 104	
macrophage or tumor cells, allowing for controlled release of drug within these cells. 105	
Furthermore, Ac-Dex degrades into neutral by-products, which avoids undesirable 106	
changes in the micro-environmental pH in the body. Finally, Ac-Dex offers the potential 107	
of targeted delivery, due to the presence of dextran chains that can be further modified 108	
with a variety of functional targeting moieties (Bachelder et al., 2008; Broaders et al., 109	
2009; Kauffman et al., 2012). 110	
 Owing to the aforementioned advantages, Ac-Dex has been widely applied in the 111	
formation of polymeric carriers for drug delivery. Porous Ac-Dex microparticles loaded 112	
with the chemotherapeutic camptothecin were developed for pulmonary delivery using 113	
emulsion techniques. These systems exhibited a respirable fraction of 37% and 114	
experimental mass mean aerodynamic diameters from 5.3 - 11.9 µm (Meenach et al., 115	
2012). Ac-Dex nanoparticle systems have been investigated in the application of protein 116	
delivery for immunotherapy (Broaders et al., 2009), gene delivery to phagocytic and non-117	
phagocytic cells (Cohen et al., 2010), tandem delivery of peptide and chemotherapeutic 118	
for controlled combination chemotherapy (Cui et al., 2011), delivery of the host-mediated 119	
compound AR-12 (Arno Therapeutics; formerly known as OSU-03012) for the treatment 120	
of Leishmania donovani (Collier et al., 2016), and the control of Salmonella infections 121	
(Collier et al., 2016). Both Ac-Dex nanoparticles and microparticles loaded with 122	
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horseradish peroxidase have been evaluated to improve vaccine stability outside cold 123	
chain conditions (Kanthamneni et al., 2012). 124	
 Despite this work, there is no comprehensive study on using Ac-Dex as an 125	
excipient for dry powder aerosol formulations produced via spray drying. In this study, 126	
we aimed to develop and characterize dry powder pulmonary delivery systems based on 127	
spray-dried Ac-Dex particles with capabilities of (a) delivering therapeutics to the deep 128	
lung, (b) targeting the particles to a particular location within the lungs, and (c) releasing 129	
therapeutics at a controlled rate. Previous studies have shown that: (a) aerodynamic 130	
diameter (da) determines the region of the lungs where particles will deposit, where 131	
particles with an da of 1 - 5 µm tend to deposit in the deep lung region (Meenach et al., 132	
2013a); (b) geometric size plays an important role in the cellular uptake of particles, 133	
where nanoscale particles (approximately 150 nm) tend to escape phagocytic uptake (He 134	
et al., 2010), while particles larger than 1 µm will suffer from macrophage clearance in 135	
the alveoli (Kho et al., 2010); and (c) the drug release rate of Ac-Dex particles can be 136	
tuned by modifying the synthesis time of the Ac-Dex polymer (Kauffman et al., 2012; 137	
Meenach et al., 2012). 138	
 To prepare the engineered particle systems, two types of Ac-Dex with rapid or 139	
slow degradation rates were synthesized. Nanocomposite microparticle (nCmP) and 140	
microparticle (MP) systems were formulated using both kinds of Ac-Dex as the 141	
excipient. Curcumin was used as model drug owing to its high hydrophobicity (similar to 142	
many other pulmonary therapeutics) and fluorescence (allowing for easy detection). The 143	
nCmP were prepared by spray drying an aqueous suspension of CUR-loaded Ac-Dex 144	
nanoparticles (NP, 200 nm) and the solid MP were formulated by spray drying a solution 145	
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of Ac-Dex and CUR in a solution of tetrahydrofuran (THF) and acetone. We hypothesize 146	
that upon pulmonary administration, the nCmP will deposit in the deep lung, decompose 147	
into free NP, and facilitate the sustained release of drug to the targeted site, while the MP 148	
will remain the original size after deposition in the deep lung region. A schematic of the 149	
described particle preparation and design is shown in Figure 1. Overall, the goal of the 150	
described research was the initial development and physicochemical characterization of 151	
dry powder Ac-Dex aerosol particle systems with the potential for effective delivery of 152	
therapeutics. 153	
 154	
2. MATERIALS AND METHODS 155	
 156	
2.1 Materials  157	
 Dextran from Leuconostoc mesenteroides (9000-11000 MW), pyridinium p-158	
toluenesulfonate (PPTS, 98%), 2-methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥ 159	
99%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), poly(vinyl alcohol) (PVA, MW 160	
13,000-23,000, 87-89% hydrolyzed), dichloromethane (DCM, anhydrous, ≥ 99.8%), 161	
deuterium chloride (DCl, 35 weight % in D2O, 99 atom % D), Tween® 80, curcumin, 162	
sodium acetate (≥ 99%), acetic acid solution (1.0 N), acetone (≥ 99.8%), tetrahydrofuran 163	
(THF, ≥ 99%), and methanol (anhydrous, ≥ 99.9%)  were obtained from Sigma–Aldrich 164	
(St. Louis, MO). Deuterium oxide (D2O, 99.8% atom D) was obtained from Acros 165	
Organics (Geel, Belgium). Phosphate buffered saline (PBS) was obtained from Fisher 166	
Scientific (Somerville, NJ). Hydranal® KF reagent was obtained from Fluka Analytical. 167	
 168	
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2.2 Synthesis and NMR Analysis of Acetalated Dextran (Ac-Dex)  169	
 Ac-Dex was synthesized as described previously (Bachelder et al., 2008) with 170	
minor modifications. 1 g of lyophilized dextran and 25 mg of PPTS were dissolved in 10 171	
mL of anhydrous DMSO. The resulting solution was reacted with 5 mL of 2-MOP under 172	
nitrogen gas for 5 minutes to prepare Ac-Dex with a rapid degradation rate (Ac-Dex-173	
5min) or for 3 hours to prepare Ac-Dex with a slower degradation rate (Ac-Dex-3h). The 174	
reaction was quenched with 1 mL of TEA. The reaction mixture was then precipitated in 175	
basic water (water and TEA, pH 9), vacuum filtered, and lyophilized (−50 °C, 0.023 176	
mbar) for 24 hours to yield a solid product.   177	
 The cyclic-to-acyclic (CAC) ratio of acetal coverage and degrees of total acetal 178	
coverage per 100 glucose molecules was confirmed by 1H NMR spectroscopy (Bruker 179	
300 MHz NMR, MA). 10 mg of Ac-Dex was added to 700 µL of D2O and was 180	
hydrolyzed with 30 µL of DCl prior to analysis. The hydrolysis of one cyclic acetal group 181	
produces one acetone molecule whereas one acyclic acetal produces one acetone and one 182	
methanol molecule each. Consequently, from the normalized integration of peaks related 183	
to acetone, methanol, and the carbon ring of dextran, the CAC ratio of acetal coverage 184	
and degrees of total acetal coverage per 100 glucoses were determined.  185	
 186	
2.3 Formation of CUR-Loaded Ac-Dex Nanoparticles (CUR NP) 187	
 Curcumin-loaded nanoparticles (CUR NP) were prepared via an oil/water 188	
emulsion solvent evaporation using Ac-Dex-5min, Ac-Dex-3h, or a mixture of both types 189	
of Ac-Dex (50 % w/w). 49 mg of Ac-Dex and 1 mg of CUR were dissolved in 1 mL of 190	
DCM over an ice bath, establishing the organic phase. The aqueous phase was comprised 191	
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of 6 mL of 3% PVA in PBS and was added to the organic phase. The resulting mixture 192	
was sonicated (Q500 Sonicator, Qsonica, Newtown, CT) for 30 seconds with a 1 second 193	
on/off pulse at 70% amplitude. The emulsion was transferred to a spinning solution of 194	
0.3% PVA in PBS and was stirred for 3 hours to allow for evaporation of the organic 195	
solvent and particle hardening. The solution was then centrifuged at 19802 ⨯g for 20 196	
minutes to collect the nanoparticles. Nanoparticles were washed once with DI water, 197	
redispersed in 0.1% PVA, and lyophilized (−50 °C, 0.023 mbar) for 48 hours. The 198	
resulting NP systems were: CUR NP-5min (made of Ac-Dex-5min only), CUR NP-3h 199	
(made of Ac-Dex-3h only), and CUR NP-h (50 wt% Ac-Dex-5min and 50 wt% Ac-Dex-200	
3h). 201	
 202	
2.4 Formulation of CUR Nanocomposite Microparticles (CUR nCmP) via Spray 203	
Drying 204	
 CUR nCmP were prepared via the spray drying of an aqueous suspension of each 205	
type of CUR NP (0.5%, w/v) using a Büchi B-290 spray dryer (Büchi Labortechnik, AG, 206	
Switzerland) in open mode. The CUR NP suspension was sonicated for 10 minutes 207	
before spray drying. The spray drying conditions were as follows: inlet temperature of 60 208	
°C (outlet temperature of 32 ± 2 °C), 0.7 mm nozzle diameter, atomization gas flow rate 209	
of 414 L/h using dry nitrogen, aspiration rate of 28 m3/h, pump rate of 0.9 mL/min, and 210	
nozzle cleaner rate of 3. The resulting nCmP were separated in a high-performance 211	
cyclone, dried for 15 minutes in the spray dryer	 for further removal of residual water, 212	
collected in a sample collector, and stored in amber glass vials in a desiccator at −20°C. 213	
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nCmP comprised of each kind of NP described previously were produced: nCmP-5min, 214	
nCmP-3h, and nCmP-h, correspondingly.  215	
 216	
2.5 Formulation of CUR Microparticles (CUR MP) via Spray Drying  217	
 Solid curcumin-loaded microparticles (CUR MP) were prepared via the spray 218	
drying of an organic solution comprised of Ac-Dex and CUR using a Büchi B-290 spray 219	
dryer in closed mode. The organic solutions were prepared by dissolving CUR and Ac-220	
Dex (2:98 w/w) in an organic solvent comprised of 85% acetone and 15% THF (v/v) at a 221	
solids concentration of 2% (w/v). The spray drying conditions were as follows: inlet 222	
temperature of 60 °C (outlet temperature of 40 ±  2 °C), 0.7 mm nozzle diameter, 223	
atomization gas flow rate of 414 L/h using UHP dry nitrogen, aspiration rate of 40 m3/h, 224	
pump rate of 3 mL/min, and nozzle cleaner rate of 0. The resulting MP were separated in 225	
a high-performance cyclone, dried for 15 minutes in the spray dryer	 for further removal 226	
of residual solvent, collected in a sample collector, and stored in amber glass vials in a 227	
desiccator at −20°C. The resulting MP were: MP-5min (from Ac-Dex-5min), MP-3h 228	
(from Ac-Dex-3h), and MP-h (from 50 wt% Ac-Dex-5min and 50 wt% Ac-Dex-3h). 229	
 230	
2.6 Particle Size, Size Distribution, and Zeta Potential Analysis 231	
 The average diameter, size distribution, and zeta potential of the original NP and 232	
the NP released from the dispersion of nCmP in water were measured by dynamic light 233	
scattering (DLS) using a Malvern Nano Zetasizer (Malvern Instruments, Worcestershire, 234	
UK). The original NP and nCmP were dispersed in DI water (pH = 7, 0.3 mg/mL) prior 235	
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to analysis. All experiments were performed in triplicate with a scattering angle of 173° 236	
at 25 °C.  237	
 238	
2.7 Particle Morphology and Shape Analysis via Scanning Electron Microscopy 239	
(SEM) 240	
 The shape and surface morphology of the nCmP and MP were evaluated by SEM 241	
using a Zeiss SIGMA VP Field Emission-Scanning Electron Microscope (FE-SEM) 242	
(Germany). Particle samples were placed on aluminum SEM stubs (Ted Pella, Inc., 243	
Redding, CA) with double-sided adhesive carbon tabs. The samples were coated with a 244	
thin film of a gold/palladium alloy using a BIO-RAD sputter coating system at 20 µA for 245	
60 seconds under argon gas. Images were captured at 8 kV at various magnifications. The 246	
geometric mean diameter and standard deviation of the MP were measured digitally from 247	
SEM images using ImageJ software (Rasband, 1997-2016). Representative micrographs 248	
(5000x magnification) for each sample were analyzed by measuring the diameter of at 249	
least 300 particles. 250	
 251	
2.8 Tapped Density Evaluation of nCmP and MP 252	
 The tapped density of the particles was measured as described previously with 253	
minor modifications (Tomoda et al., 2008). 35 - 40 mg of particles was weighed into a 254	
glass tube. The tube was tapped 200 times to ensure efficient packing of the particles and 255	
then the volume occupied by the particles was measured using calipers. The density of 256	
the particles was then determined by the following equation: 257	
 258	
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m      (1)
V
r =  259	
 260	
where ρ is the tapped density, m is the particle mass, and V is the volume occupied by the 261	
particles as determined by measuring the height of the particles in the tube with a known 262	
diameter (5 mm). The theoretical mass median aerodynamic diameter (MMADT) of the 263	
particles was then calculated using the following equation: 264	
 265	
T *d   MM   2A ( )D  
r
r
=
 
266	
 267	
where d is the geometric diameter determined by ImageJ, ρ is the tapped density of the 268	
particles, and ρ* = 1 g/cm3, which is the reference density of solid polymer. 269	
 270	
2.9 Drug Loading Analysis of nCmP and MP 271	
 The drug loading and encapsulation efficiency of CUR nCmP and CUR MP were 272	
determined via fluorescence spectroscopy (Biotek Cytation 3, Winooski, VT). All 273	
particle samples were dissolved in DMSO and were evaluated at 420 nm (excitation) and 274	
520 nm (emission). The CUR drug loading and encapsulation efficiency (EE) of the 275	
particles were determined by the following equations: 276	
 277	
mass of CUR loaded in particlesDrug loading =       (3) 
mass of particles
mass of CUR loaded in particlesEncapsulation efficiency (EE) =   100%      (4)
initial mass of CUR in particles
´
 278	
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 279	
2.10 In Vitro Drug Release from nCmP and MP 280	
 The in vitro release profiles of CUR from nCmP and MP were determined via the 281	
release of suspended particles (0.5 mg/mL, 1.5 mL) in modified phosphate buffer (0.1 M, 282	
pH = 7.4, 0.5 wt% Tween® 80) and modified acetate buffer (0.1 M, pH = 5, 0.5 wt% 283	
Tween® 80). The particle suspensions were incubated at 37 °C and 100 rpm (Digital Heat 284	
Block and ORBi shaker, Benchmark Scientific, Edison, NJ). At various time points, 285	
particle samples were centrifuged at 23102 ⨯g for 5 minutes at 4 °C to isolate the NP. 286	
200 µL of supernatant was withdrawn and replaced by the same amount of fresh modified 287	
buffer in each sample. The withdrawn solutions were mixed with an equal volume of 288	
DMSO and analyzed for CUR content via fluorescence spectroscopy using the same 289	
method described for drug loading. The release data was fitted to several commonly 290	
utilized drug release models (Supplemental Information Section S.1) to elucidate the 291	
mechanism of drug release of Ac-Dex particles. The coefficient of determination (R2) 292	
was applied to test the applicability of the described release models. 293	
 294	
2.11 Differential Scanning Calorimetry (DSC) 295	
 The thermal phase transitions of nCmP, MP, and their raw components were 296	
determined via DSC using a TA Q10 DSC system (TA Instruments, New Castle, DE, 297	
USA) equipped with an automated computer-controlled TA instruments DSC refrigerated 298	
cooling system. 1 - 3 mg of sample was weighed into Tzero™ alodine-coated aluminum 299	
pans that were hermetically sealed. The sealed pans were placed into the DSC furnace 300	
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along with an empty sealed reference pan. The heating range was 0 – 200 °C at a heating 301	
rate of 10 °C/min. 302	
 303	
2.12 Powder X-Ray Diffraction (PXRD) 304	
 The crystalline states of nCmP, MP, and its raw components were examined by 305	
PXRD using a Rigaku Multiflex X-ray diffractometer (The Woodlands, TX) with a Cu 306	
Kα radiation source (40 kV, 44 mA). The samples were placed on a horizontal quartz 307	
glass sample holder (3 mm) prior to analysis. The scan range was 5 – 60° in 2Θ with a 308	
step width of 0.1 and scan rate of 1 °/min. 309	
 310	
2.13 Karl Fischer Coulometric Titration 311	
 The water content of nCmP and MP was quantified by Karl Fischer (KF) titration 312	
using a 737 KF coulometer (Metrohm, Riverview, FL). 5 mg of powder was dissolved in 313	
anhydrous methanol. The resulting solution was injected into the KF reaction cell filled 314	
with Hydranal® KF reagent and then the amount of water was analyzed. Pure solvent was 315	
also injected for use as a background sample. 316	
 317	
2.14 In Vitro Aerosol Dispersion Performance with the Next Generation Impactor 318	
(NGI) 319	
 In vitro aerosol dispersion performance of nCmP and MP was evaluated using a 320	
Next Generation Impactor™ (NGI™, MSP Corporation, Shoreview, MN) equipped with 321	
a stainless steel induction port (USP throat adaptor) attachment and stainless steel 322	
gravimetric insert cups. The NGI™ was coupled with a Copley TPK 2000 critical flow 323	
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controller, which was connected to a Copley HCP5 vacuum pump (Copley Scientific, 324	
United Kingdom). The air flow rate (Q) was measured and adjusted to 60 L/min before 325	
each experiment in order to model the flow rate in a healthy adult lung. Glass fiber filters 326	
(55 mm, Type A/E, Pall Life Sciences, PA) were placed in the gravimetric insert cups for 327	
stages 1 through 7 to minimize particle bounce or re-entrapment (Meenach et al., 2013a) 328	
and these filters were weighed before and after the experiment to determine the particle 329	
mass deposited on each stage. Approximately 10 mg of powder was loaded into a 330	
hydroxypropyl methylcellulose (HPMC, size 3, Quali-V®, Qualicaps® Inc., Whitsett, NC, 331	
USA) capsule and the capsule was placed into a human dry powder inhaler device 332	
(HandiHaler, Boehringer Ingelheim Pharmaceuticals, CT) attached to a customized 333	
rubber mouthpiece connected to the NGI™. Three HPMC capsules were loaded and 334	
released in each measurement and experiments were performed in triplicate. The NGI™ 335	
was run with a delay time of 10 s and running time of 10 s. For Q = 60 L/min, the 336	
effective cutoff diameters for each stage of the impactor were given from the 337	
manufacturer as: stage 1 (8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 µm); stage 4 (1.66 338	
µm); stage 5 (0.94 µm); stage 6 (0.55 µm); and stage 7 (0.34 µm). Our previous study on 339	
the relationship between particle mass distribution and payload distribution showed that 340	
no significant difference existed between the drug amount and particle mass in each 341	
chamber of NGI (p > 0.05), indicating that the drug was uniformly dispersed in both 342	
CUR-MP and CUR-nCmP (Figure S1). The fine particle fraction (FPF), respirable 343	
fraction (RF), and emitted dose (ED) were calculated as follows: 344	
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mass of particles on Stages 2 through 7Fine particle fraction (FPF) =   100%      (5)
initial particle mass loaded into capsules
mass of particles on Stages 2 through 7Respirable fraction (RF) = 
total 
´
  100%      (6)
particle mass on all stages
initial mass in capsules - final mass remaining in capsulesEmitted dose (ED) =   100%      (7)
initial mass in capsules
´
´
345	
 346	
 The experimental mass median aerodynamic diameter (MMADE) and geometric 347	
standard deviation (GSD) for the particles were determined using a Mathematica® 348	
program written by Dr. Warren Finlay (Meenach et al., 2013a; W, 2008). 349	
 350	
2.15 Statistical Analysis 351	
 All measurements were performed in at least triplicate. Values are given in the 352	
form of mean ± standard deviation. The statistical significance of the results was 353	
determined using analysis of variance (ANOVA) and student’s t-test. A p-value of <0.05 354	
was considered statistically significant. 355	
 356	
3. RESULTS AND DISCUSSION 357	
 358	
3.1 Preparation and Characterization of Ac-Dex and Curcumin Nanoparticles 359	
 360	
3.1.1 NMR Analysis of Ac-Dex 361	
 Successful synthesis of Ac-Dex was confirmed by 1H NMR (Figure S2). Ac-Dex-362	
5min exhibited 61.2% cyclic acetal coverage (CAC) and 71.6% total conversion of -OH 363	
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groups, while Ac-Dex-3h exhibited 82.5% CAC and 80.0% total conversion of -OH 364	
groups, which matched our previous results (Wang et al., 2016; Wang and Meenach, 365	
2016). The Ac-Dex with longer synthesis time (Ac-Dex-3h) exhibited a higher CAC, 366	
which was in accordance with previous studies. An increase in CAC is known to decrease 367	
polymer degradation and ultimately, the drug release rate, due to the slower degradation 368	
of the cyclic acetal groups on the Ac-Dex backbone (Bachelder et al., 2008; Broaders et 369	
al., 2009). Ac-Dex-3h also showed a higher total conversion of -OH groups, which could 370	
be a result the longer reaction time. This higher total acetal coverage is favorable in the 371	
enhancement of the stability of the PVA coating of nanoparticles (data not shown), thus 372	
ensuring small particle size and narrow size distribution. 373	
 374	
3.1.2 Dynamic Light Scattering (DLS) Analysis of Original and Redispersed CUR NP 375	
 Average nanoparticle size, size distribution/polydispersion index (PDI), and zeta 376	
potential are shown in Table 1. No significant changes in NP size, PDI, or zeta potential 377	
was found between the original and redispersed NP (p < 0.05), indicating that the CUR 378	
NP maintained their properties after redispersion. The original and redispersed NP 379	
exhibited an average diameter of approximately 200 nm, which is in the desirable range 380	
to avoid macrophage clearance and mucus entrapment (Kho et al., 2010). The low PDI 381	
value denotes a narrow size distribution of the NP, and the slightly negatively charged 382	
surface of nanoparticles, as measured by zeta potential, is desirable in order to reduce the 383	
interactions with negatively charged mucin fibers present in airway mucus (Lai et al., 384	
2009). According to our preliminary experiments (data not shown), a low total 385	
conversion of -OH groups on the Ac-Dex results in NP with larger sizes and PDI due to 386	
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NP agglomeration. This phenomenon could be a result of the reduced hydrophobicity of 387	
Ac-Dex with fewer -OH groups converted to acetal groups, which leads to insufficient 388	
absorption of PVA on the NP surface. However, the Ac-Dex in this study was prepared to 389	
produce NP with small sizes and low PDI, as the total conversion of -OH groups was 390	
kept in a higher range to prevent NP agglomeration. 391	
 392	
3.2 Preparation and Characterization of Nanocomposite Microparticles (nCmP) and 393	
Microparticles (MP) 394	
 395	
3.2.1 Morphology, Sizing, and Size Distribution 396	
 CUR nCmP displayed a wrinkled surface with visibly encapsulated NP as seen in 397	
Figure 2 and Figure S3. The raisin-like morphology of the nCmP can be attributed to 398	
the early formation of nanoparticle shells in the solution droplets during spray drying, 399	
which determines the geometric size of nCmP. As the drying process proceeds, the 400	
remaining solvent evaporates from the droplet center, resulting in hollow particles that 401	
tend to shrink (Atalar and Dervisoglu, 2015; Gu et al., 2015).  402	
 CUR MP were collapsed, wrinkled spheres as seen in Figures 2D-F. Altering the 403	
Ac-Dex composition of the particles had no impact on particle morphology. The 404	
geometric diameters (dg) of the CUR nCmP and MP systems are shown in Table 2. All of 405	
the MP dg were approximately 1 µm in size, which is reported to make the particles 406	
vulnerable to macrophage uptake (Sung et al., 2009). In contrast, the NP released from 407	
nCmP systems can escape macrophage clearance upon reaching the deep lung. 408	
 409	
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3.2.2 Analysis of Particle Density 410	
 The density of the particles was determined via tapped density measurements, as 411	
shown in Table 2. CUR nCmP exhibited tapped density values around 0.12 g/cm3, while 412	
the MP system showed values around 0.05 g/cm3. These density values are relatively low 413	
compared with the raw materials (~1 g/cm3), which can be attributed to the wrinkled 414	
morphology and hollow structures of the particle systems. It has been reported that 415	
particles > 1 µm in diameter with greater density will deposit in the lungs by 416	
sedimentation (Heyder, 2004). Therefore, the increased density of CUR nCmP system as 417	
compared to MP could enhance their rate of deposition into the deep lung. 418	
 419	
3.2.3 Loading and In Vitro Release of CUR 420	
 CUR was successfully encapsulated into both the nCmP and MP systems as seen 421	
in Table 2. The MP systems prepared via closed mode, organic spray drying exhibited 422	
higher encapsulation efficiency (EE, > 50%) than the nCmP systems (approximately 423	
30%) prepared in open mode in aqueous solutions. The lower EE of the nCmP can be 424	
attributed to the EE of the original CUR-loaded NP, which was also approximately 30% 425	
(Table S1). The spray drying process had no influence on the CUR loading and EE for 426	
the nCmP systems (p < 0.05), which indicates that the drug loading of nCmP systems can 427	
be determined during NP preparation.  428	
 Results of the in vitro release of CUR from both nCmP and MP systems in 429	
modified phosphate (pH 7.4) and acetate (pH 5) buffers at physiological temperature 430	
(37°C) are reported in Figure 3 as the percentage of cumulative drug released over time. 431	
As shown in Table S2, the particle systems exhibited shorter release durations and 432	
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increased release of CUR (p < 0.05) at acidic pH with the exception of nCmP-5min, 433	
which only exhibited a shorter release duration. These results are in accordance with 434	
previous studies (Meenach et al., 2012; Vehring, 2008). The release profiles suggest that 435	
the drug will be released at significantly higher rates once the carrier particles reach an 436	
acidic environment. This can allow Ac-Dex particles the ability to provide controlled 437	
release of a therapeutic payload in cells and tissue with lower pH values, such as tumor 438	
cells and macrophages. In contrast, if the carrier particles remain in the extracellular or 439	
neutral pH environments, the release rate can be reduced, which can minimize systemic 440	
and local cytotoxicity (Meenach et al., 2012). 441	
 In addition, the nCmP systems exhibited faster release than the MP systems, 442	
which is likely due to the larger surface area available in the nano-sized delivery systems. 443	
Upon reaching an aqueous environment, the nCmP dissociate into nanoparticles with 444	
large surface areas and a PVA coating that facilitates particle dispersity, while the MP 445	
may agglomerate due to their highly hydrophobic, uncoated surfaces. As a result, the 446	
nCmP systems undergo faster polymer degradation and drug diffusion, resulting in a 447	
faster release of payloads than MP at both acidic and physiologic pH.  448	
 Particles comprised of Ac-Dex-3h exhibited slower release rates than those 449	
comprised of Ac-Dex-5min, indicating that the drug release rate can be controlled by the 450	
polymer reaction time. At pH 7.4, particles made of Ac-Dex-h exhibited a drug release 451	
rate between Ac-Dex-5 min and Ac-Dex-3h, suggesting that the ratio of different types of 452	
Ac-Dex can also act as an important factor in adjusting the release profiles of particle 453	
systems. Nevertheless, the drug release rates of the Ac-Dex particles at pH 5 did not 454	
follow this trend, which could be explained by one of the following: (1) the release 455	
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profile of Ac-Dex particles is polymer degradation controlled and the decomposition of 456	
the Ac-Dex matrix is greatly impacted by the release buffer pH and (2) the release profile 457	
of Ac-Dex particles is both polymer degradation and drug diffusion controlled. In 458	
previous studies, drug release from Ac-Dex particles was associated with Ac-Dex 459	
degradation (Bachelder et al., 2008; Kauffman et al., 2012; Meenach et al., 2012). 460	
However, Ac-Dex degradation may result in the surface erosion of particles, formation of 461	
large pores in the particles that facilitate drug diffusion, or both at the same time. As a 462	
result, the drug release profile could be controlled by drug diffusion through water-filled 463	
pores (diffusion controlled), polymer erosion on the particle surface (erosion controlled), 464	
or both drug diffusion and surface erosion (diffusion and erosion controlled), respectively 465	
(Broaders et al., 2009).  466	
 In order to further illustrate the mechanism of drug release of Ac-Dex particles, 467	
we fitted the CUR release data to several commonly utilized drug release models, 468	
including: (1) a first order model and (2) Hixson–Crowell model for drug dissolution-469	
controlled release, (3) Higuchi model modified to fit burst release at time 0, (4) 470	
Korsmeyer–Peppas model and (5) Baker–Lonsdale for drug diffusion-controlled release, 471	
(6) Hopfenberg model for surface erosion-controlled release, (7) Baker’s model for both 472	
degradation and diffusion-controlled release, and (8) Weibull model as a general 473	
empirical equation to describe a dissolution or release process (Bohrey et al., 2016; Costa 474	
and Sousa Lobo, 2001; Kamaly et al., 2016; Seidlitz and Weitschies, 2012; Shuwisitkul, 475	
2011). The coefficient of determinations (R2) of the fit for the models are summarized in 476	
Table S3. The modified Higuchi and Baker–Lonsdale models exhibited higher R2 477	
compared with other models, indicating that the drug release profiles of all Ac-Dex 478	
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particles at both acidic and neutral pH was due primarily to drug diffusion. For Baker’s 479	
model (Shuwisitkul, 2011) that describes a degradation and diffusion process, the optimal 480	
coefficient k was 0, thus the equation of Baker’s model exhibited the same form as the 481	
equation for the Higuchi model. Since the degradation of Ac-Dex was observable during 482	
the release experiments, the release profiles of Ac-Dex particles can be explained by the 483	
mechanism of drug diffusion through water-filled pores (Kamaly et al., 2016). In the 484	
process of drug diffusion through water-filled pores, water was absorbed by Ac-Dex 485	
particles and filled in the pores of the polymer matrix, through which the drug diffused 486	
into the buffer. As polymer degraded, both pore size and number increased, resulting in 487	
enhanced drug release. Therefore, the reaction time of Ac-Dex affected the drug release 488	
rate significantly by controlling the formation of pores of particle matrix but not polymer 489	
degradation on the surface. Meanwhile, the water absorption into the particles may also 490	
influence the drug release rate, which can be supported by the fact that Ac-Dex-3h had a 491	
higher ratio of total hydrophobic acetalated group conversion than Ac-Dex-5min. The 492	
fitted release curves using modified Higuchi model are shown in Figure S4 along with 493	
the original data points. The model was modified to fit the burst release at time 0 of the 494	
particle systems, which can be attributed to CUR being initially available on the surface 495	
of the particles. The nCmP systems exhibited a high release at time 0 because the 496	
nanoparticle suspension was sonicated before spray drying to form a uniform dispersion, 497	
which may cause CUR release in to the suspension.  498	
 499	
3.3.4 Karl Fischer Titration 500	
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 The residual water content of CUR nCmP and MP is shown in Table 2. The water 501	
content of nCmP system was approximately 8%, while that of MP system was 502	
approximately 6%. The lower water content of MP samples is likely due to the absence of 503	
water during the closed mode spray drying process. All particle systems showed 504	
acceptable water content for aerosol formulations. In general, reducing the water content 505	
in inhalable dry powders can significantly improve their dispersion properties and 506	
enhance the stability of the powders during storage (Hickey et al., 2007; Mohammadi et 507	
al., 2010). Correspondingly, low water content in inhalable dry powders is highly 508	
favorable for efficient dry powder aerosolization and effective particle delivery 509	
(Mohammadi et al., 2010; Wu et al., 2013).   510	
 511	
3.3.5 Differential Scanning Calorimetry 512	
 Figure 4 shows DSC thermograms of the raw materials used in particle 513	
preparation and the final CUR nCmP and CUR MP systems. Both the raw Ac-Dex-5min 514	
and Ac-Dex-3h displayed endothermic phase transition peaks due to melting (Tm) near 515	
170 °C.  The peaks were broad because of the wide size distribution of Ac-Dex polymer 516	
crystallites. None of the CUR nCmP systems exhibited a peak corresponding to Ac-Dex 517	
melting, which indicates that the Ac-Dex was transformed in an amorphous state by rapid 518	
precipitation during NP formation. The CUR MP systems exhibited broad phase 519	
transition peaks near 160 °C, which corresponds to the melting of Ac-Dex. This phase 520	
transition shifted to the lower temperature range, indicating a reduction in the 521	
crystallinity of Ac-Dex after the spray drying process.  522	
  523	
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3.3.6 Powder X-ray Diffraction (PXRD) 524	
 X-ray diffraction diffractograms of the raw materials, physical mixture of Ac-Dex 525	
and CUR, CUR nCmP, and CUR MP are shown in Figure 5. No peaks were present for 526	
either raw Ac-Dex samples, suggesting an irregular distribution or lack of Ac-Dex 527	
crystallites. The absence of diffraction peaks from Ac-Dex is quite different from 528	
commercialized polymers such as PLGA, which exhibits strong XRD characterization 529	
peaks (Mohammadi et al., 2010). This phenomenon is likely because the Ac-Dex was 530	
collected by rapid precipitation in water, which prevents the formation of large polymer 531	
crystallites. Strong peaks were present for raw CUR indicating that it was in crystalline 532	
form prior to spray drying. XRD diffractograms of the physical mixture, CUR nCmP and 533	
CUR MP were absent of any diffraction peaks corresponding to raw CUR, which was 534	
due to the dilution effect of Ac-Dex. The results obtained from the XRD diffractograms 535	
confirmed those from DSC thermograms, which show that raw CUR was converted to 536	
amorphous forms during the particle manufacturing process. 537	
    538	
3.3.7 In Vitro Aerosol Dispersion Performance Using Next Generation Impactor (NGI) 539	
 In vitro aerosol dispersion performance properties of the nCmP were evaluated 540	
using a Next Generation Impactor™ coupled with a human DPI device (Figure 6 and 541	
Figure 7). The results indicated that the formulated nCmP and MP are favorable for 542	
efficient dry powder aerosolization and effective targeted pulmonary delivery. The 543	
experimental mass mean aerodynamic diameter (MMADE) values of all particle systems 544	
were approximately 2 µm, while the geometric standard deviation (GSD) values were 2 - 545	
3 µm. The MMADE values were within the range of 1 - 5 µm that is required for 546	
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predominant deposition of particles into the deep lung region (Meenach et al., 2013b), 547	
which would be desirable to deliver therapeutics for the treatment of both local and 548	
systematic diseases through the lung. The theoretical mass mean aerodynamic diameter 549	
(MMADT, Table 2), calculated using the geometric diameter and tapped density, was 550	
lower than the experimental MMAD. This discrepancy is likely due to particle 551	
agglomeration, which increased the geometric size of the dry powder particulates. All of 552	
the particle systems exhibited low tapped density values, which supports the hypothesis 553	
that the particles are likely hollow. This can also be attributed to their wrinkled surface 554	
morphology, as seen in SEM analysis. The GSD values were within the range of those 555	
previously reported and the respirable fraction (RF), fine particle fraction (FPF), and 556	
emitted dose (ED) values were all higher than reports from similar systems (Meenach et 557	
al., 2013a; Meenach et al., 2013b; Ungaro et al., 2006). The formulated Ac-Dex particle 558	
systems are expected to achieve an improved therapeutic effect with a reduced amount of 559	
payloads by effectively delivering drugs into the deep lung region.  560	
 561	
4. CONCLUSIONS  562	
 Two types of pulmonary delivery systems were successfully formulated using Ac-563	
Dex with two different degradation rates. The resulting CUR MP were wrinkled spheres 564	
(approximately 1 µm), while nCmP were similar in size with wrinkled surfaces that 565	
showed the presence of nanoparticles. The variations in the drug release rates from the 566	
Ac-Dex particles were influenced by the Ac-Dex reaction time, ratio of two types of Ac-567	
Dex, and the particle size, which could be easily tuned during the manufacturing process. 568	
The pH value of the environment also had a significant influence on the release profiles, 569	
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allowing the Ac-Dex particles to release the payload in a controlled fashion. All nCmP 570	
and MP systems exhibited desirable properties as dry powder inhalation formulations, 571	
including small aerodynamic diameters, which is suitable for deep lung delivery, low 572	
water content, which is favorable for particle storage, and amorphization of a crystalline 573	
payload, which improves the efficiency of drug dissolution. Overall, the engineered Ac-574	
Dex aerosol particle systems have the potential for targeted delivery of therapeutics into 575	
the deep lung.  576	
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TABLES AND FIGURES 729	
 730	
Table 1. Average diameter (as measured by dynamic light scattering), polydispersity 731	
index (PDI), and zeta potential (ZP) of CUR-loaded nanoparticles before spray drying 732	
(NP) and after redispersion from nanocomposite microparticles (nCmP) (mean ± standard 733	
deviation, n = 3). 734	
 735	
Particle 
System  
Average 
Diameter (nm) PDI ZP (mV) 
NP-5min 192.2 ± 2.7 0.07 ± 0.03 -8.4 ± 4.1 
NP-h 201.1 ± 1.5 0.02 ± 0.01 -8.0 ± 3.7 
NP-3h 206.1 ± 1.3 0.03 ± 0.03 -7.0 ± 1.6 
nCmP-5min 199.3 ± 1.3 0.09 ± 0.02 -14.5 ± 1.0 
nCmP-h 210.2 ± 2.5 0.07 ± 0.01 -13.3 ± 1.9 
nCmP-3h 213.5 ± 2.4 0.02 ± 0.00 -11.2 ± 1.6 
 736	
Table 2. Geometric diameter (as measured by SEM imaging and ImageJ analysis), 737	
experimental mass median aerodynamic diameter (MMADE), geometric standard 738	
deviation (GSD), water content, tapped density, theoretical mean mass aerodynamic 739	
diameter (MMADT), drug loading, and drug encapsulation efficiency (EE) of nCmP and 740	
MP (mean ± standard deviation, n = 3). 741	
Particle 
System 
Geometric 
Diameter 
(µm) 
MMADE 
(µm) 
GSD 
(µm) 
Water 
Content 
(%) 
Tapped 
Density 
(g/cm3) 
MMADT 
(µm) 
Drug 
Loading 
(mg/100
mg 
particle) 
EE 
(%) 
nCmP-
5min 
1.52 ± 
0.33 
1.61 ± 
0.16 
2.37 ± 
0.24 
7.69 ± 
0.76 
0.122 ± 
0.001 
0.52 ± 
0.09 
0.57± 
0.006 
28.7 ± 
0.32 
nCmP-
h 
1.77 ± 
0.46 
2.05 ± 
0.09 
2.62 ± 
0.17 
7.89 ± 
1.56 
0.115 ± 
0.004 
0.60 ± 
0.09 
0.58 ± 
0.008 
28.4 ± 
0.42 
nCmP-
3h 
1.72 ± 
0.39 
1.89 ± 
0.09 
2.70 ± 
0.13 
7.86 ± 
0.43 
0.133 ± 
0.002 
0.64 ± 
0.12 
0.62 ± 
0.013 
31.2 ± 
0.63 
MP-
5min 
0.89 ± 
0.30 
2.38 ± 
0.06 
2.14 ± 
0.14 
6.12 ± 
1.33 
0.050 ± 
0.001 
0.21 ± 
0.03 
1.33 ± 
0.092 
66.3 ± 
4.62 
MP-h 1.26 ± 0.41 
2.21 ± 
0.23 
2.17 ± 
0.03 
5.87 ± 
1.85 
0.050 ± 
0.001 
0.29 ± 
0.32 
1.03 ± 
0.030 
51.6 ± 
1.48 
MP-3h 1.05 ± 0.36 
2.41 ± 
0.07 
2.02 ± 
0.08 
5.23 ± 
1.13 
0.052 ± 
0.001 
0.23 ± 
0.03 
1.12 ± 
0.012 
55.8 ± 
0.61 
 742	
 31 
 743	
 744	
Figure 1. Schematic depicting the synthesis of Ac-Dex (Left) and preparation of 745	
nanoparticles and formation of nanocomposite microparticles (nCmP) and microparticles 746	
(MP) (Right).  747	
 748	
 749	
Figure 2. SEM micrographs of curcumin-loaded nanocomposite microparticles (CUR 750	
nCmP) and microparticles (CUR MP) including: (A) CUR nCmP-5min, (B) CUR nCmP-751	
h, (C) CUR nCmP-3h, (D) CUR MP-5min, (E) CUR MP-h, and (F) CUR MP-3h 752	
systems. Scale bar = 2 µm. 753	
 754	
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 755	
 756	
Figure 3. In vitro drug release profiles for curcumin-loaded microparticle (MP) systems 757	
at (A) pH 5 and (B) pH 7.4 and curcumin-loaded nanocomposite microparticle (nCmP) 758	
system at (C) pH 5 and (D) pH 7.4. 759	
 760	
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 761	
Figure 4. Representative differential scanning calorimetry (DSC) thermograms of (A) 762	
raw curcumin (CUR), raw acetalated dextran-5min (Ac-Dex-5min), and raw acetalated 763	
dextran-3h (Ac-Dex-3h), (B) CUR nCmP-5min, CUR nCmP-h, and CUR nCmP-3h, and 764	
(C) CUR MP-5min, CUR MP-h, and CUR MP-3h. 765	
 766	
 767	
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 768	
Figure 5. Representative powder X-ray diffractograms (PXRD) of raw curcumin (CUR), 769	
raw acetalated dextran-5min (Ac-Dex-5min), raw acetalated dextran-3h (Ac-Dex-3h), 770	
CUR nCmP-5min, CUR nCmP-h, CUR nCmP-3h, CUR MP-5min, CUR MP-h, and CUR 771	
MP-3h. 772	
 773	
  774	
 775	
Figure 6. Aerosol dispersion performance of (A) curcumin-loaded nanocomposite 776	
microparticles (CUR nCmP) and (B) microparticles (CUR MP) as % particles deposited 777	
on each stage of the Next Generation Impactor™ (NGI™). For Q = 60 L/min, the 778	
effective cutoff diameters (D50) for each impaction stage are as follows: stage 1 (8.06 779	
µm), stage 2 (4.46 µm), stage 3 (2.82 µm), stage 4 (1.66 µm), stage 5 (0.94 µm), stage 6 780	
(0.55 µm), and stage 7 (0.34 µm) (mean ± standard deviation, n = 3). 781	
 782	
 783	
 35 
 784	
 785	
Figure 7. In vitro aerosol dispersion performance properties including fine particle dose 786	
(FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted dose (ED) for 787	
curcumin loaded nanocomposite microparticles (CUR nCmP) and microparticles (CUR 788	
MP) (mean ± standard deviation, n = 3). 789	
 790	
 791	
 792	
 793	
 794	
 795	
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SUPPLEMENTAL INFORMATION 806	
 807	
S.1 Drug Release Model Descriptions 808	
 The drug release data of the particle systems was fitted to several relevant models 809	
(equations shown below) to aid in the determination of the type of release the systems 810	
underwent. For the models that can be linearized (all except for Baker's model), the 811	
coefficient of determination (R2) was calculated to determine the applicability of the 812	
release models. For Baker's model, Microsoft Excel with Solver add-in was applied to 813	
determine the parameters that minimize the sum of squares of the residues of the model. 814	
The models, equations, and their corresponding parameters are as follows: 815	
 816	
First order model: t 0 Klog M log M t      (S1) 
2.303
= +  817	
 818	
where Mt is the amount of drug released at time t, M0 is the initial amount of drug in the 819	
solution, and K is the first order release constant. 820	
 821	
Weibull model: 
b
i(t T )m 1 exp( )      (S2)
a
- -
= -  822	
 823	
where m is the accumulated fraction of the drug released at time t, a is the scale 824	
parameter, which defines the time scale of the process, Ti is the location parameter, which 825	
represents the lag time before the onset of the dissolution or release process, and b is the 826	
shape parameter, which characterizes the shape of release curve. 827	
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 828	
Higuchi model: 1/2tM Kt b      (S3)= +  829	
 830	
where Mt is the amount of drug released at time t, K is the Higuchi dissolution constant, 831	
and b is the amount of drug released at time 0. 832	
 833	
Hixson–Crowell model: 1/3 1/30 tW W Kt      (S4)- =  834	
 835	
where W0 is the initial amount of drug in the particles, Wt is the remaining amount of 836	
drug in the particles at time t, and K is a constant characterizing the surface to volume 837	
relationship. 838	
 839	
Korsmeyer–Peppas model: nm at       (S5)=  840	
 841	
where a is a constant characterizing the structural and geometric properties of the 842	
particles, n is the release exponent, indicating the drug release mechanism, and m is the 843	
accumulated fraction of the drug released at time t. 844	
 845	
Baker–Lonsdale model: 2/33 [1 (1 m) ] m Kt      (S6)
2
- - - =  846	
 847	
where K is the release constant and m is the accumulated fraction of the drug released at 848	
time t. 849	
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 850	
Hopfenberg model: nm 1 [1 Kt(t 1)]       (S7)= - - -  851	
 852	
where K is a constant equal to k0/C0a0, where k0 is the erosion rate constant, C0 is the 853	
initial concentration of drug in the matrix, and a0 is the initial radius for particles. m is the 854	
accumulated fraction of the drug released at time t. 855	
 856	
Baker's model: kt 1/2t 0 0M A(2P e C t)       (S8)=  857	
 858	
where Mt is the amount of drug released in time t, P0 is the drug permeability, A is the 859	
total area of the particle, C0 is the drug concentration at the initial time, and k is the first-860	
order rate constant of bond cleavage of the polymer carrier.  861	
 862	
 
863	
 
864	
 
865	
 
866	
 
867	
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868	
Table S1. Drug loading and encapsulation efficiency of curcumin NP including NP-869	
5min, NP-h, and NP-3h.
 
870	
Particle 
System  
Drug Loading (mg/100mg 
particle) EE (%) 
NP-5min 0.600 ± 0.059 30.0 ± 2.95 
NP-h 0.621 ± 0.056 31.0 ± 2.82 
NP-3h 0.617 ± 0.063 30.9 ± 3.15 
 871	
Table S2. The release duration and total fraction of curcumin released from each particle 872	
system at acidic and neutral pH. 873	
  pH = 5 pH = 7.4 
Particle 
System 
Release 
Duration (h) 
Total Released 
(%) 
Release 
Duration (h) 
Total Released 
(%) 
nCmP-5min 2 92.6 8 93.6 
nCmP-h 2 63.4 12 31.5 
nCmP-3h 4 73.0 24 23.7 
MP-5min 6 78.0 24 60.6 
MP-h 12 86.4 24 52.7 
MP-3h 24 68.5 168 24.9 
 874	
 875	
 876	
 877	
 878	
 879	
 880	
 881	
 882	
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Table S3. Summary of the coefficient of determinations (R2) of all the fitted drug release 883	
models for all particle system. The model with relatively high R2 for all particle systems 884	
was regarded as a viable fit for that system. 885	
  pH = 5 
Model nCmP -5min 
nCmP 
-h 
nCmP 
-3h 
MP -
5min MP -h MP -3h 
First order 0.7835 0.8549 0.8511 0.5730 0.4848 0.7517 
Hixson–
Crowell 0.8615 0.9571 0.9613 0.8470 0.8899 0.9490 
Higuchi 
(modified) 0.9468 0.9968 0.9989 0.9867 0.9748 0.9715 
Korsmeyer–
Peppas 0.9998 0.6906 0.5050 0.8100 0.8843 0.9882 
Baker–
Lonsdale 0.8729 0.9945 0.9799 0.9065 0.9595 0.9753 
Hopfenberg 0.5497 0.8743 0.9029 0.8925 0.849 0.9276 
Weibull 0.9098 0.5773 0.2538 0.9387 0.9936 0.9353 
 886	
 887	
 888	
 889	
 890	
 891	
 892	
 893	
 894	
 895	
 896	
 897	
 898	
 899	
 900	
  pH = 7.4 
Model nCmP -5min 
nCmP 
-h 
nCmP -
3h 
MP -
5min MP -h MP -3h 
First order 0.8084 0.7345 0.7574 0.3797 0.8290 0.6414 
Hixson–
Crowell 0.9312 0.8021 0.9482 0.7696 0.9117 0.8185 
Higuchi 
(modified) 0.9573 0.8758 0.9732 0.9369 0.8288 0.9462 
Korsmeyer–
Peppas 0.8990 0.5374 0.9457 0.8828 0.9349 0.9708 
Baker–
Lonsdale 0.9709 0.8172 0.9089 0.9283 0.9141 0.9079 
Hopfenberg 0.8493 0.8678 0.9685 0.7462 0.8241 0.8526 
Weibull 1.0000 0.5235 0.7905 0.9783 0.8897 0.8963 
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 901	
Figure S1. Relationship between particle mass distribution and curcumin (CUR) 902	
distribution in all chambers of NGI for (A) CUR-nCmP and (B) CUR-MP. 903	
 904	
 905	
 906	
 907	
Figure S2. NMR analysis of Ac-Dex where peaks using during analysis include 3.4-4.0 908	
ppm for dextran (Hring and HC6), 3.36 ppm for methanol, and 2.08 ppm for acetone. 909	
Cyclic acetal coverage (CAC) and total conversion of -OH group were calculated by the 910	
following equations:	 911	
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( )
( )
Total area of  3 dextran peaksNormalization factor NF
Methanol Pe
 =            
6
 = 
 
ak AreaMethanol per glucose
3 NF
Acetone Peak AreaAcetone per glucose
6 NF
Cyclic acetal coverage CAC Aceton
= 
 = e pe  ( r gl
´
´
ucose ethanol per glucose)
Acetone per glucose ethanol per glucose)Total conversion of  OH gro
M  100%
(2 M =   100%ups
3
´
´
-
´ -
-
912	
 913	
 914	
 915	
Figure S3. Zoomed in images of CUR-nCmP including: (A) CUR nCmP-5min, (B) CUR 916	
nCmP-h, (C) CUR nCmP-3h.	Scale bar = 2 µm. 917	
 918	
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 919	
Figure S4. Original data and fitted curves of in vitro drug release profiles for curcumin 920	
(CUR) nCmP (A and B) and MP systems (C and D) including CUR nCmP-5min, CUR 921	
nCmP-h, CUR nCmP-3h, CUR MP-5min, CUR MP-h, and CUR MP-3h at pH = 5 (A and 922	
C) and pH = 7.4 (B and D). 923	
 924	
 925	
Figure S5. Structure of acetalated dextran (Ac-Dex). 926	
 927	
 928	
 929	
